Aptus Capital Advisors LLC Boosts Stock Holdings in Encompass Health Corporation $EHC

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Aptus Capital Advisors LLC grew its holdings in Encompass Health Corporation (NYSE:EHC - Free Report) by 12.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 99,828 shares of the company's stock after acquiring an additional 11,132 shares during the period. Aptus Capital Advisors LLC owned about 0.10% of Encompass Health worth $10,111,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of EHC. Colonial Trust Co SC acquired a new position in shares of Encompass Health in the fourth quarter worth $29,000. Transce3nd LLC acquired a new position in shares of Encompass Health in the fourth quarter worth $40,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Encompass Health by 749.0% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 416 shares of the company's stock worth $42,000 after acquiring an additional 367 shares in the last quarter. Arlington Trust Co LLC grew its stake in shares of Encompass Health by 22.9% in the first quarter. Arlington Trust Co LLC now owns 671 shares of the company's stock worth $68,000 after acquiring an additional 125 shares in the last quarter. Finally, Johnson Financial Group Inc. acquired a new position in shares of Encompass Health in the fourth quarter worth $72,000. Institutional investors and hedge funds own 97.25% of the company's stock.

Encompass Health Stock Performance

EHC traded down $0.67 on Friday, reaching $122.76. The company had a trading volume of 798,000 shares, compared to its average volume of 895,065. Encompass Health Corporation has a 1 year low of $87.85 and a 1 year high of $124.67. The stock has a market capitalization of $12.36 billion, a PE ratio of 24.02, a P/E/G ratio of 2.16 and a beta of 0.86. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.76. The stock has a 50-day moving average price of $116.38 and a 200-day moving average price of $110.27.

Encompass Health (NYSE:EHC - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $1.40 EPS for the quarter, beating analysts' consensus estimates of $1.20 by $0.20. Encompass Health had a net margin of 9.22% and a return on equity of 17.83%. The business had revenue of $1.46 billion during the quarter, compared to analysts' expectations of $1.43 billion. During the same period in the prior year, the company earned $1.11 earnings per share. The business's revenue was up 12.0% compared to the same quarter last year. Encompass Health has set its FY 2025 guidance at 5.120-5.340 EPS. As a group, research analysts forecast that Encompass Health Corporation will post 4.8 EPS for the current fiscal year.

Encompass Health Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Wednesday, October 1st will be issued a $0.19 dividend. The ex-dividend date of this dividend is Wednesday, October 1st. This is a positive change from Encompass Health's previous quarterly dividend of $0.17. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.6%. Encompass Health's dividend payout ratio is currently 14.87%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on EHC. Barclays lifted their price objective on shares of Encompass Health from $118.00 to $129.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Truist Financial lifted their price objective on shares of Encompass Health from $135.00 to $140.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. UBS Group lifted their price objective on shares of Encompass Health from $130.00 to $140.00 and gave the stock a "buy" rating in a research report on Wednesday, August 6th. Stephens raised shares of Encompass Health from an "overweight" rating to a "strong-buy" rating and set a $135.00 price objective for the company in a research report on Thursday, June 5th. Finally, Royal Bank Of Canada lifted their price objective on shares of Encompass Health from $110.00 to $125.00 and gave the stock an "outperform" rating in a research report on Monday, April 28th. One investment analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $134.00.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.